Premium
Risk assessment of drug‐induced drug reaction with eosinophilia and systemic symptoms ( DRESS ) syndrome: a disproportionality analysis using the French Pharmacovigilance Database
Author(s) -
Agier M.S.,
Boivin N.,
Maruani A.,
Giraudeau B.,
Gouraud A.,
Haramburu F.,
Jean Pastor M.J.,
Machet L.,
JonvilleBera A.P.
Publication year - 2016
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.14649
Subject(s) - pharmacovigilance , drug , medicine , eosinophilia , drug reaction , adverse drug reaction , pharmacology , database , immunology , computer science
The drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) is a severe cutaneous drug-induced reaction with a mortality rate which can reach 10%(1) . This syndrome was first described for anticonvulsant drugs (carbamazepine, phenytoin and phenobarbitone) and the same symptoms were subsequently observed with a variety of other drugs(2, 3) . DRESS is a very rare adverse drug reaction (ADR), such that it is difficult to estimate its true incidence for each drug. There is only one study reporting estimate of DRESS incidence, and the values are in the range of 1 case per 1,000 to 10,000 drug exposures(4) . Prospective studies would provide better estimates, but may be too long to be feasible. Because there are too few cases to calculate the true incidence of DRESS for any single drug, we sought to use disproportionality measures(5,6) (also called the case/non case method) to categorize the risk of DRESS syndrome according to the drug involved. This article is protected by copyright. All rights reserved.